Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized open-label study of prophylaxis for GPRC5D-related oral taste events
NL-OMON58694Phase 2Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2025
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of talquetamab and ramantamig in multiple myeloma (MM) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Rate of occurrence of taste dysfunction dysgeusia, Rate of occurrence of severe dysgeusia and 3 more. Started Oct 2025; status: recruiting.
02
Drugs
talquetamabramantamig
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NL-OMON58694.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58694.